- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04259112
Effect of Pneumoperitoneum and Neuromuscular Block on Renal Function in Diabetes Patients
October 3, 2020 updated by: Huang YuGuang, Peking Union Medical College Hospital
Effect of Pneumoperitoneum Pressure and the Extent of Neuromuscular Block on Renal Function in Patients With Diabetes Undergoing Laparoscopic Pelvic Surgery
In this single center, double-blind, randomized controlled clinical trial, we will include 648 diabetes patients aged 18-70 undergoing laparoscopic pelvic tumor resection.
They will be randomized to the following four groups: high-pressure pneumoperitoneum (10mmHg)+ deep neuromuscular block group, high-pressure pneumoperitoneum (15mmHg)+moderate neuromuscular block group, low-pressure pneumoperitoneum + deep neuromuscular block group and low-pressure pneumoperitoneum+moderate neuromuscular block group.
Deep neuromuscular block is defined as post tetanic count (PTC) 1-2, and low neuromuscular block is defined as train-of-four (TOF) twitch 1-2.
The outcomes will be indicators for acute kidney injury and surgical condition.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
In this single center, double-blind, randomized controlled clinical trial, we will include 648 diabetes patients aged 18-70 undergoing laparoscopic pelvic tumor resection under general anesthesia.
They will be randomized to the following four groups: high-pressure pneumoperitoneum (10mmHg)+ deep neuromuscular block group, high-pressure pneumoperitoneum (15mmHg)+moderate neuromuscular block group, low-pressure pneumoperitoneum + deep neuromuscular block group and low-pressure pneumoperitoneum+moderate neuromuscular block group.
Neuromuscular block will be induced by rocuronium bolus and maintained by a continuous infusion of rocuronium.
Deep neuromuscular block is defined as PTC 1-2, and low neuromuscular block is defined as train-of-four TOF twitch 1-2.
The primary outcome will be serum Cystatin C level, and the secondary outcomes will be serum creatine level, urinary sediment, intraoperative urine output, duration of surgery, surgical space condition and occurrence bucking and body movement.
Study Type
Interventional
Enrollment (Anticipated)
648
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaohan Xu, M.D.
- Phone Number: 86-15210560817
- Email: smartannie@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18-70;
- American Society of Anesthesiologist physical status (ASA) II-Ⅲ;
- Diagnosed of diabetes;
- Undergoing elective laparoscopic pelvic tumor resection under general anesthesia;
- Estimated duration of operation >2h;
Exclusion criteria:
- Not willing to participate in the study or not able to sign the informed consent;
- Diagnosed of other kidney diseases except diabetic nephropathy;
- Severe renal insufficiency defined as serum creatine level > 2 times the upper limit of normal, or urine output < 0.5ml/kg/h, or estimated glomerular filtration rate < 60ml/h;
- Severe liver, lung or heart dysfunction;
- Known or suspect neuromuscular disease;
- Use of drugs that may affect neuromuscular block monitoring;
- Severe diabetic neuropathy or other peripheral neuropathy;
- Known or suspect allergy to general anesthetics;
- Family history of malignant hyperthermia;
- Previous history of pelvic surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: high pressure + deep block
Intra-abdominal pressure will be set to 12-15 mmHg during the surgery.
Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
|
High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
Deep neuromuscular block is defined as PTC 1-2.
|
Experimental: high pressure + moderate block
Intra-abdominal pressure will be set to 12-15 mmHg during the surgery.
Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
|
High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
Moderate neuromuscular block is defined as TOF twitch 1-2.
|
Experimental: low pressure + deep block
Intra-abdominal pressure will be set to 7-10 mmHg during the surgery.
Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
|
Deep neuromuscular block is defined as PTC 1-2.
Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
|
Experimental: low pressure + moderate block
Intra-abdominal pressure will be set to 7-10 mmHg.
Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
|
Deep neuromuscular block is defined as PTC 1-2.
Moderate neuromuscular block is defined as TOF twitch 1-2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum cystatin C (CysC) level
Time Frame: 30 minutes before pneumoperitoneum insufflation
|
CysC is a sensitive indicator for early kidney injury, and can be used to estimate glomerular filtration rate (GFR).
|
30 minutes before pneumoperitoneum insufflation
|
Serum cystatin C (CysC) level
Time Frame: 30 minutes after pneumoperitoneum deflatation
|
CysC is a sensitive indicator for early kidney injury, and can be used to estimate glomerular filtration rate (GFR).
|
30 minutes after pneumoperitoneum deflatation
|
Serum cystatin C (CysC) level
Time Frame: Postoperative 24 hours
|
CysC is a sensitive indicator for early kidney injury, and can be used to estimate glomerular filtration rate (GFR).
|
Postoperative 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum creatine level
Time Frame: 30 minutes before pneumoperitoneum insufflation
|
Creatine is also an indicator for kidney injury
|
30 minutes before pneumoperitoneum insufflation
|
Serum creatine level
Time Frame: 30 minutes after pneumoperitoneum deflatation
|
Creatine is also an indicator for kidney injury
|
30 minutes after pneumoperitoneum deflatation
|
Serum creatine level
Time Frame: Postoperative 24 hours
|
Creatine is also an indicator for kidney injury
|
Postoperative 24 hours
|
The volume of intraoperative urine output
Time Frame: At the end of the surgery
|
A urine tube will be inserted just before the surgery, so the urine can be drained into a bag.
The volume of urine in the bag at the end of the surgery will be the volume of intraoperative urine output.
|
At the end of the surgery
|
The presence of isomorphic or dysmorphic erythrocyte in urinary sediment
Time Frame: Postoperative day 1
|
Erythrocyte in urinary sediment is also an indicator of renal injury.
|
Postoperative day 1
|
Duration of surgery
Time Frame: Intraoperative
|
Duration of surgery is an indicator for procedure difficulty
|
Intraoperative
|
Leiden-surgical rating scale
Time Frame: The moment when trocars are introduced into pelvic cavity, and then every 15 minutes till the end of surgery.
|
We will use Leiden surgical rating scale (Martini et al.) to assess surgical condition.
It is a 5-point scale, the minimum and maximum values are 1 and 5, respectively.
Higher score indicates better surgical condition.
|
The moment when trocars are introduced into pelvic cavity, and then every 15 minutes till the end of surgery.
|
The number of bucking and body movement during the surgery
Time Frame: Intraoperative
|
The occurrence of bucking or body movement is an indicator for the sufficiency of muscle relaxant.
|
Intraoperative
|
Renal tissue oxygen saturation
Time Frame: Intraoperative
|
Renal oxygen saturation is an indicator for renal tissue oxygenation.
|
Intraoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yuguang Huang, M.D., Peking Union Medical College Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2020
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
February 2, 2020
First Submitted That Met QC Criteria
February 5, 2020
First Posted (Actual)
February 6, 2020
Study Record Updates
Last Update Posted (Actual)
October 6, 2020
Last Update Submitted That Met QC Criteria
October 3, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-ml
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
Clinical Trials on high pressure
-
Hospital Civil de GuadalajaraUnknownIntraocular Pressure | Intracranial Pressure Increase | Children, Only | Trauma, BrainMexico
-
Abant Izzet Baysal UniversityCompletedBreast Cancer Lymphedema | Lymphedema of Upper Limb | Edema ArmTurkey
-
Imam Abdulrahman Bin Faisal UniversityUnknownLung Disease | Undergoing Thoracosocpic SurgerySaudi Arabia
-
Aalborg University HospitalCompletedPneumoperitoneum | Acute Kidney Injury | KidneyDenmark
-
University of Maryland, BaltimoreTerminated
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
University of Toledo Health Science CampusUnknown
-
Universidad Complutense de MadridFundación de Investigación Biomédica - Hospital Universitario de La PrincesaCompletedHealthy Adult | VenipunctureSpain
-
Emory UniversityVirginia Polytechnic Institute and State UniversityCompleted
-
University of MaiaCompletedSports Physical TherapyPortugal